dsRNA Agents Targeting GPAM for Liver Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is currently no effective treatment for chronic fibro-inflammatory liver diseases such as liver fibrosis, NASH, and NAFLD, which are associated with increased lipid accumulation, and the standard of care primarily focuses on lifestyle modifications and managing comorbidities.
Innovation Solution
Development of double-stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) gene, using specific dsRNA compositions to form the RNA-induced silencing complex (RISC) and cleave GPAM RNA transcripts, thereby reducing GPAM activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifestyle modification and comorbidity management are used as standard of care, then treatment simplicity is maintained, but therapeutic effectiveness is insufficient for chronic fibro-inflammatory liver diseases
Solution Approach 1:
The patent introduces dsRNA agents as intermediary molecules that mediate between the administered therapy and the target GPAM gene. These agents specifically bind to GPAM mRNA transcripts and recruit RNA-induced silencing complexes (RISC), thereby mediating gene silencing without requiring direct manipulation of the gene itself. This intermediary approach enables effective treatment of chronic fibro-inflammatory liver diseases while maintaining relatively simple administration protocols.
Solution Approach 2:
The patent replaces mechanical/lifestyle intervention approaches with a molecular-level mechanism. Instead of relying on lifestyle modifications and comorbidity management, the invention uses dsRNA agents that exploit the natural RNA interference pathway to specifically silence GPAM expression. This substitution of mechanism enables more reliable therapeutic effectiveness by directly targeting the molecular pathway involved in lipid metabolism and inflammation.
2Reliability
If dsRNA agents are developed to target GPAM gene expression, then therapeutic effectiveness is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent employs parameter changes in the design of dsRNA agents, specifically optimizing the length, sequence composition, and structural characteristics of the RNA molecules. By carefully controlling these parameters, the invention achieves high therapeutic effectiveness through specific binding to GPAM transcripts while managing manufacturing complexity. The defined structural parameters enable standardized production protocols.
Solution Approach 2:
The patent applies local quality principles by designing dsRNA agents with specific regional characteristics - certain regions are optimized for target binding specificity while other regions are optimized for stability and RISC recruitment. This localized optimization of different segments of the dsRNA molecule enables effective gene silencing while simplifying the overall manufacturing process by allowing modular design and synthesis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents effectively inhibit GPAM expression, potentially mitigating lipid accumulation and addressing chronic fibro-inflammatory liver diseases by targeting the underlying metabolic pathways.
Implementation Method 1
dsRNA agents that target and inhibit the expression of glycerol-3-phosphate acyltransferase 1, mitochondrial (GPAM) gene, using specific dsRNA compositions to form the RNA-induced silencing complex (RISC) and cleave GPAM RNA transcripts
Data Source
Figure 1
AI summary
The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the GPAM gene, as well as methods of inhibiting expression of GPAM, and methods of treating subjects that would benefit from reduction in expression of GPAM, such as subjects having a GPAM-associated disease, disorder, or condition, using such dsRNA compositions.